ライフサイエンスコーパス: heart block

1 ardia and atrioventricular (AV) dysfunction (heart block).

2 s; and 6) the introduction of the concept of heart block.

3 chronically instrumented dogs with complete heart block.

4 from inherited cardiac arrhythmias, notably heart block.

5 insight into the pathogenesis of congenital heart block.

6 rial fibrillation without producing complete heart block.

7 led him to discover the mechanism of partial heart block.

8 mportant risk factor for having a child with heart block.

9 RS complex, 4 resulted in transient complete heart block.

10 ite their strong association with congenital heart block.

11 larly 52Ro, in the development of congenital heart block.

12 rothers of another family had arrhythmia and heart block.

13 intractable ventricular arrhythmias, and/or heart block.

14 s 69%; P=0.034), but with a 23% incidence of heart block.

15 diogenic shock, cardiac arrest, and complete heart block.

16 4 years) received a PPM due to postoperative heart block.

17 reat profound bradycardia caused by complete heart block.

18 support in both rats and pigs with complete heart block.

19 prior asystole from sinus arrest or complete heart block.

20 a bilateral ocular involvement and complete heart block.

21 a bilateral ocular involvement and complete heart block.

22 similar time course to that of postsurgical heart block.

23 adverse events on all cases was queried for heart block.

24 icular conduction in a rat model of complete heart block.

25 PM4 have been linked to progressive familial heart block.

26 lar nodal cells, accounting for the observed heart block.

27 r contractions, tachycardia, and high-degree heart block.

28 sistent with bradyarrhythmia and progressive heart block.

29 lower success rate and a higher incidence of heart block.

30 a may be characteristic of an acute stage of heart block.

31 ns to ventricular arrhythmias and congenital heart block.

32 5%) who required permanent pacing because of heart block.

33 was frequently followed by atrioventricular heart block.

34 ne of the most common pathologies underlying heart blocks.

35 int occurred in 14.3% consisting of 1 (2.9%) heart block, 1 (2.9%) femoral artery dissection, and 3 (

36 n fraction <60% (1.72; 1.22-2.40; P = .002), heart block (2.22; 1.41-3.47; P = .001), tachyarrhythmia

37 r arrhythmia (9 patients, or 14 percent), or heart block (3 patients, or 5 percent), although in some

38 s 13.1%; P<0.001), as were rates of complete heart block (3.5% versus 11.2%; P<0.001) and new-onset l

39 z type II atrioventricular block or complete heart block; (3) ventricular fibrillation; (4) ventricul

40 mortality; reduced first- and second-degree heart block 4.6- and 4-fold, respectively; and prevented

41 Of the 139 patients with postoperative heart block, 68 required PPM.

42 0 (versus intermittent CHB or second degree heart block; 87% versus 58%; P=0.001).

43 portantly, DMPK+/- mice develop first-degree heart block, a conduction defect strikingly similar to t

44 lar conduction with transition into complete heart block after 160 Gy.

45 One procedure was complicated by complete heart block after ablation of a high-risk midseptal AP.

46 used to identify patients with postoperative heart block after CHS between January 1, 1960, and Decem

47 t pacemaker placement (PPM) in patients with heart block after congenital cardiac surgery.

48 help identify patients at risk for complete heart block after septal reduction procedures for HCM.

49 onatal lupus (cardiac NL) include congenital heart block and cardiomyopathy.

50 bradyarrhythmia characterized by progressive heart block and impaired ventricular depolarization.

51 others with a previous child with congenital heart block and in 3 of 74 pregnancies (4%) in mothers w

52 the near universal association of congenital heart block and maternal Abs to SSA/Ro and SSB/La, the i

53 ors, but not muscarinic receptors, prevented heart block and mortality versus controls.

54 e birth to children with complete congenital heart block and photosensitive skin lesions.

55 egment depression, complete atrioventricular heart block and right precordial ST segment elevation.

56 nt mice develop progressive atrioventricular heart block and significant ultrastructural changes in b

57 nother patient with syncope had intermittent heart block and survived as the result of pacing feature

58 s anticipated, 3 patients developed complete heart block and underwent pacemaker implantation, wherea

59 cts with progressive development of complete heart block and various arrhythmias, all of whom died su

60 into the pathogenesis of cardiac conduction, heart block and ventricular fibrillation.

61 ular anterior wall of adult dogs in complete heart block and with backup electronic pacemakers.

62 e >=3 s, anytime sinus pause >=6 s, complete heart block, and a composite end point demonstrated an a

63 with small hearts, bradycardia, intermittent heart block, and a markedly reduced cardiac output.

64 osite of cardiogenic shock, arrest, complete heart block, and cardiac death.

65 ptomatic atrial or ventricular arrhythmia or heart block, and cardiovascular death.

66 irth, developed significant bradycardia with heart block, and died within the first weeks after birth

67 ctural defects but have progressive complete heart block, and massive trabecular muscle overgrowth fo

68 01 for atrial fibrillation, atrioventricular heart block, and pacemaker implantation).

69 endocarditis surgery, aortocavitary fistula, heart block, and prosthetic valve endocarditis.

70 echanisms of arrhythmogenesis: focal ectopy, heart block, and reentry.

71 e ventricular contractions, atrioventricular heart block, and ventricular tachycardia.

72 diomyopathy are at risk for acute high-grade heart block, and, in this cohort, bradycardic events rep

73 ailure, cardiac arrest, arrhythmia, complete heart block, and/or stroke requiring hospitalization <1

74 o deaths were caused by development of acute heart block; another patient with syncope had intermitte

75 pharmacological therapies of chronic SND and heart block are desirable.

76 sociated cardiac defects, operative history, heart block, arrhythmias and tricuspid (i.e., systemic a

77 s conduction system abnormalities that cause heart block, arrhythmias, and sudden death are more comm

78 ay lead to adverse outcomes such as advanced heart block, arrhythmias, cardiomyopathy, or death.

79 His/Purkinje system is required for type II heart block, as seen clinically.

80 with neonatal lupus erythematosus (NLE) and heart block, as well as patients with Sjogren's syndrome

81 aily to prevent the recurrence of congenital heart block associated with anti-SSA/Ro (anti-Sjogren's

82 t groups more likely to develop third-degree heart block associated with Lyme carditis is essential t

83 risk for atrial and ventricular arrhythmias, heart block, asystole, development of pulmonary congesti

84 ing the DN allele displayed slow conduction, heart block, atrial fibrillation, ventricular tachycardi

85 ate cardiac erosions, thrombus formation and heart block; (b) the transcatheter closure of muscular v

86 evelop ventricular arrhythmias or high-grade heart block because the treatment is different and drama

87 e elinogrel arms, but there were no cases of heart block, bradycardia, hypotension, or liver failure.

88 or until a significant arrhythmia (asystole, heart block, bradycardia, supraventricular or ventricula

89 e molecular basis of atrial fibrillation and heart block but also may suggest targets for the develop

90 eading to sudden cardiac death from complete heart block, but no longer developed DCM or the other ph

91 a significantly higher incidence of complete heart block, but the risk was reduced with contrast echo

92 e branch block (RBBB), and 0.6% had complete heart block (CHB) after myectomy.

93 dence and determinants of permanent complete heart block (CHB) after nonsurgical septal reduction the

94 cardiac tissue from a fetus with congenital heart block (CHB) and an age-matched control.

95 etermine the temporal occurrence of complete heart block (CHB) and ventricular tachyarrhythmia (VT) a

96 description and understanding of congenital heart block (CHB) came in the 1970s with the observation

97 ce rate of anti-SSA/Ro-associated congenital heart block (CHB) is 17%.

98 Congenital heart block (CHB) is a conduction abnormality characteri

99 Congenital heart block (CHB) is a disease that affects the offsprin

100 Complete heart block (CHB) is a life-threatening condition that c

101 Congenital heart block (CHB) is an autoimmune disease that affects

102 It is a widely held view that congenital heart block (CHB) is caused by the transplacental transf

103 lesion of autoantibody-associated congenital heart block (CHB) is fibrosis of the conducting tissue.

104 Congenital heart block (CHB) is presumed to be caused by transplace

105 Autoimmune associated congenital heart block (CHB) may result from pathogenic cross-talk

106 ewed all cases of second degree and complete heart block (CHB) on POD 0 from August 2009 through Dece

107 Identification of isolated congenital heart block (CHB) predicts, with near certainty, the pre

108 ce rates of autoimmune-associated congenital heart block (CHB) using information from the Research Re

109 relevant in autoimmune-associated congenital heart block (CHB) where the obligate factor is a materna

110 e report 16 infants with complete congenital heart block (CHB) who developed late-onset dilated cardi

111 Congenital heart block (CHB), associated with antibodies to SS-A/Ro

112 In congenital heart block (CHB), binding of maternal anti-SSA/Ro Abs t

113 necessary for the development of congenital heart block (CHB), the low frequency suggests that fetal

114 in maternal anti-SSA/Ro-mediated congenital heart block (CHB).

115 atrioventricular node leading to congenital heart block (CHB).

116 ated genes in the pathogenesis of congenital heart block (CHB).

117 3 children (22 with rash, 35 with congenital heart block [CHB], 26 unaffected siblings) and 58 mother

118 of the literature on catheterization-induced heart block (CIHB) was published >30 years ago.

119 imary cardiac arrest, and sustained complete heart block, classified by a reviewer blinded to preoper

120 ld, respectively; and prevented third-degree heart block compared with controls.

121 is associated with cardioskeletal myopathy, heart block, delayed growth and early postnatal death.

122 Complete heart block developed in 11 patients, who then required

123 A young woman with complete heart block died suddenly.

124 Destructive counterparts include familial heart block ending in fatal arrhythmias, similar results

125 after in utero identification of congenital heart block, especially in fetuses with associated myoca

126 utoantibodies with the genesis of congenital heart block, female BALB/c mice were immunized with huma

127 systemic lupus erythematosus, and congenital heart block from anti-Ro52 Ab-positive mother.

128 plays progressive muscle wasting, cataracts, heart block, gonadal atrophy, insulin resistance and neu

129 ce developing cardiomyopathy associated with heart block, impaired repolarization, and ventricular ar

130 ications included tamponade in 1 patient and heart block in 2 patients.

131 We describe the occurrence of complete heart block in a patient with Sjogren's syndrome.

132 anisms resulting in immune-mediated complete heart block in a small subset of 'at-risk' fetuses is un

133 ed K(+) channel (IKACh) could rescue SSS and heart block in Cav1.3(-/-) mice.

134 There was a trend toward more congenital heart block in fetuses of women with previously affected

135 ink between ETV1 and bundle branch block and heart block in humans.

136 entricular contractions and atrioventricular heart block in junctin-null mice.

137 t, second, and third-degree atrioventricular heart block in pediatric patients.

138 at hydroxychloroquine may prevent congenital heart block in pregnancies exposed to SSA/Ro antibodies.

139 t ventricular ejection fraction and complete heart block in the LMNA DCM cohort.

140 Incidence of third-degree heart block in the STZ+RH group was 5.6%, 7.8-fold less

141 radually progressive development of complete heart block in young people often is associated with car

142 inically relevant porcine models of complete heart block, intramyocardially injected TBX18 mRNA provi

143 Complete heart block is a common complication after NSRT.

144 Heart block is a potential complication of both catheter

145 Heart block is associated with substantial morbidity and

146 Congenital heart block is considered a model of passively acquired

147 Childhood morbidity with heart block is high, with 63% eventually requiring pacem

148 ti-SSA/Ro-associated third-degree congenital heart block is irreversible, prompting a search for earl

149 The timing of heart block is not random; bradycardia is most often ide

150 ant to the development of anti-Ro-associated heart block, it can nevertheless be affected.

151 ssociated with an increased risk of complete heart block, it should not be performed routinely.

152 rse effects include infections, bradycardia, heart blocks, macular edema, infusion reactions, injecti

153 ta suggest that patients affected by SSS and heart block may benefit from IKACh suppression achieved

154 able analysis identified older age, complete heart block, MV repair without annuloplasty ring, and th

155 ded tamponade (n = 4), pericarditis (n = 3), heart block (n = 1, prior to radiofrequency application)

156 Other adverse events included complete heart block (n=2) and increased atrioventricular valve r

157 ses fulminant heart failure, arrhythmias, or heart block, necessitating aggressive immunosuppression,

158 or for the composite of in-hospital death or heart block (noninferiority, P<0.001; superiority, P=0.0

159 Transient second- and third-degree heart block occurred at higher doses (300/600, 450/900,

160 Postoperative complete heart block occurred in 20 patients (18.5%).

161 Heart block occurred in 3 of 16 pregnancies (19%) in mot

162 nt heart rate or during pacing if Wenckebach heart block occurred.

163 Heart block occurs with increasing age.

164 patients with pacing indications of complete heart block or atrioventricular nodal ablation (LP: 10.3

165 ugs or other environmental stressors such as heart block or heart failure.

166 ailure predicted IGCM, and presentation with heart block or more than nine weeks of symptoms predicte

167 ailure predicted IGCM, and presentation with heart block or more than nine weeks of symptoms predicte

168 ers without a previous child with congenital heart block or rash (P=0.067).

169 =3 s, anytime sinus pause of >=6 s, complete heart block, or a composite of these bradyarrhythmias fr

170 mber of deaths (4 versus 1), final degree of heart block, or requirement for a pacemaker (14 versus 1

171 omposite outcome of in-hospital mortality or heart block, outcomes were compared (sequential noninfer

172 s6795970 is associated with a higher risk of heart block (P < 0.05) and a lower risk of ventricular f

173 sence of arrhythmias (P > 0.2), first-degree heart block (P = 0.12), bundle-branch block (P > 0.2), a

174 8.6%) had serious adverse events of complete heart block, peri-hepatic bleeding, and rupture of tricu

175 of having a subsequent child with congenital heart block ranges between 12-16%.

176 autoantibodies only after identification of heart block/rash in a child.

177 Other complications included heart block requiring a pacemaker (13%) and thrombosis (

178 y consisted of third-degree atrioventricular heart block requiring a pacemaker.

179 Complications after initial MVR included heart block requiring pacemaker (16%), endocarditis (6%)

180 gnificantly increased the risk of a complete heart block requiring pacemaker implantation (8.1% versu

181 by a rise in the incidence of postoperative heart block requiring permanent pacemaker (PPM) implanta

182 Heart block requiring permanent pacemaker implantation w

183 cal risk, unsuitable septal perforators, and heart block requiring permanent pacemakers.

184 Four patients (3%) developed heart block requiring permanent pacing after the procedu

185 Six patients (12%) developed complete heart block requiring permanent pacing, three of whom ha

186 -D reconstruction of SN network in clarified heart blocks revealed significant changes in the physiol

187 is of neonatal lupus syndrome and congenital heart block reveals important information about prospect

188 gene transfer of SEK-1(KR) to the adult rat heart blocks SAPK activation by pressure overload, demon

189 ution of channel expression was intermittent heart block seen.

190 One survivor developed complete heart block shortly after the study visit.

191 heral artery disease, second or third degree heart block, stroke (ischaemic, haemorrhagic, and unspec

192 hol ablation, but with a higher incidence of heart block than in cases where only surgery is performe

193 d arrhythmias, but their combination induced heart block that could be abrogated by nicotinic recepto

194 d by heart failure, ventricular arrhythmias, heart blocks, thromboembolic phenomena, and sudden death

195 nt patients who exhibit evidence of neonatal heart block, treatment with dexamethasone is preferred o

196 bundle-branch disorder progressive familial heart block type I (PFHBI) and isolated cardiac conducti

197 -in a large family with progressive familial heart block type I and showed that these mutations preve

198 mon adverse effects associated with TAVI are heart block, vascular complications, and renal failure.

199 Isolated heart block was associated with a 7.8% case fatality rat

200 e antibodies to have a child with congenital heart block was at or below one in 50.

201 Congenital heart block was diagnosed in utero in 12 patients and at

202 dence of pacemaker implantation for complete heart block was higher (22% vs. 2% in surgery; p = 0.02)

203 Second-degree heart block was increased 12- and 6.8-fold in the STZ an

204 A high rate of complete heart block was noted within the MVR group (37.5%).

205 Transient complete heart block was seen in 4 patients; the duration was <5

206 s cause rhythm disturbances such as complete heart block, which can be fatal.

207 (Preventive Approach to Congenital Heart Block With Hydroxychloroquine [PATCH]; NCT01379573